Drug intelligence / Profile preview

metoprolol + bisoprolol + carvedilol

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

This is a hypothetical combination of three beta-adrenergic receptor antagonists (beta blockers): metoprolol, bisoprolol, and carvedilol. All three are established medications used primarily in the management of cardiovascular diseases such as heart failure with reduced ejection fraction (HFrEF), hypertension, and post-myocardial infarction care. Metoprolol and bisoprolol are cardioselective beta-1 blockers, while carvedilol is a non-selective beta blocker that also blocks alpha-1 adrenergic receptors. These agents reduce heart rate, decrease myocardial contractility, lower blood pressure, and improve survival in patients with heart failure[1][2][5]. Carvedilol’s additional alpha-1 blockade leads to vasodilation. There is no evidence or clinical guideline supporting the use of all three agents simultaneously as a fixed combination; typically only one is chosen based on patient-specific factors[2][8].

Brand names
ZebetaCoregToprol XLKapspargo Sprinkle
02

Targets

ADRB1 (β1)ADRA1 (Alpha-1 adrenergic receptor family)

Beyond the preview

Go deeper on metoprolol + bisoprolol + carvedilol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metoprolol + bisoprolol + carvedilol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call